RU2021115958A - Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы - Google Patents
Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы Download PDFInfo
- Publication number
- RU2021115958A RU2021115958A RU2021115958A RU2021115958A RU2021115958A RU 2021115958 A RU2021115958 A RU 2021115958A RU 2021115958 A RU2021115958 A RU 2021115958A RU 2021115958 A RU2021115958 A RU 2021115958A RU 2021115958 A RU2021115958 A RU 2021115958A
- Authority
- RU
- Russia
- Prior art keywords
- group
- cells
- tumor
- compound
- psma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| US62/311,697 | 2016-03-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133693A Division RU2749399C2 (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021115958A true RU2021115958A (ru) | 2021-07-12 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021115958A RU2021115958A (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
| RU2018133693A RU2749399C2 (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133693A RU2749399C2 (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (enExample) |
| EP (3) | EP3925952B1 (enExample) |
| JP (3) | JP7073270B2 (enExample) |
| KR (4) | KR20230147751A (enExample) |
| CN (3) | CN114716387B (enExample) |
| AU (1) | AU2017238181B2 (enExample) |
| BR (1) | BR112018069507A2 (enExample) |
| CA (1) | CA3018709A1 (enExample) |
| CL (1) | CL2018002683A1 (enExample) |
| CY (1) | CY1124487T1 (enExample) |
| DK (2) | DK3925952T3 (enExample) |
| ES (2) | ES2972148T3 (enExample) |
| FI (1) | FI3925952T3 (enExample) |
| HR (2) | HRP20240215T1 (enExample) |
| HU (2) | HUE055607T2 (enExample) |
| LT (2) | LT3925952T (enExample) |
| MX (1) | MX384823B (enExample) |
| PH (1) | PH12018502048A1 (enExample) |
| PL (2) | PL3433238T3 (enExample) |
| PT (2) | PT3925952T (enExample) |
| RS (2) | RS65188B1 (enExample) |
| RU (2) | RU2021115958A (enExample) |
| SA (1) | SA518400103B1 (enExample) |
| SI (2) | SI3433238T1 (enExample) |
| TR (1) | TR201813644T1 (enExample) |
| WO (1) | WO2017165473A1 (enExample) |
| ZA (1) | ZA201806389B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018031809A1 (en) | 2016-08-10 | 2018-02-15 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| EP3544960A1 (en) * | 2016-11-23 | 2019-10-02 | Cancer Targeted Technology LLC | Albumin-binding psma inhibitors |
| CN110291401B (zh) | 2016-12-14 | 2023-04-11 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| WO2019115547A1 (en) * | 2017-12-11 | 2019-06-20 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| PL3498308T3 (pl) * | 2017-12-13 | 2025-03-31 | Sciencons AS | Kompleks zawierający związek celujący w PSMA połączony z radionuklidem ołowiu lub toru |
| KR20250021601A (ko) * | 2018-02-06 | 2025-02-13 | 우니베르시타트 하이델베르크 | Fap 억제제 |
| BR112020016040A2 (pt) * | 2018-02-06 | 2020-12-08 | The Johns Hopkins University | Ureia-poliaminocarboxilatos radiohalogenados que utilizam psma como alvo para radioterapia contra câncer |
| SG11202009649RA (en) | 2018-03-30 | 2020-10-29 | Futurechem Co Ltd | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
| AU2019287595B2 (en) * | 2018-04-27 | 2024-10-31 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| BR112021005931A2 (pt) * | 2018-09-28 | 2021-06-29 | Universität Heidelberg | composto, complexo e composição farmacêutica |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| WO2020139012A1 (ko) * | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| JP7608378B2 (ja) * | 2019-07-02 | 2025-01-06 | ノバルティス アーゲー | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
| CN120441497A (zh) * | 2019-07-02 | 2025-08-08 | 先进加速器应用意大利公司 | 前列腺特异性膜抗原（psma）配体及其用途 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| WO2021219719A1 (en) | 2020-04-29 | 2021-11-04 | Advanced Accelerator Applications (Italy) Srl | Methods for radiolabelling psma binding ligands and their kits |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| WO2022101352A1 (en) | 2020-11-12 | 2022-05-19 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| EP4247798B1 (en) * | 2020-11-19 | 2025-08-27 | Novartis AG | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| WO2022266499A1 (en) * | 2021-06-17 | 2022-12-22 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| JP2025506001A (ja) | 2022-02-09 | 2025-03-05 | ノバルティス アーゲー | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
| EP4637843A2 (en) * | 2022-12-21 | 2025-10-29 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5680409B2 (ja) * | 2007-06-26 | 2015-03-04 | ザ ジョンズ ホプキンス ユニバーシティ | 前立腺特異膜抗原（ｐｓｍａ）の標識阻害剤、生物学的評価およびイメージング剤としての使用 |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| AU2009322171A1 (en) * | 2008-12-05 | 2011-06-30 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
| CA3257131A1 (en) * | 2009-03-19 | 2025-04-15 | The Johns Hopkins University | PSMA-TARGETING COMPOUNDS AND RELATED USES |
| ES2732060T3 (es) * | 2011-08-05 | 2019-11-20 | Molecular Insight Pharm Inc | Inhibidores radiomarcados del antígeno de membrana específico de la próstata |
| CN113149921B (zh) * | 2011-11-30 | 2024-11-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| PL2943227T3 (pl) * | 2013-01-14 | 2018-02-28 | Molecular Insight Pharmaceuticals, Inc. | Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego |
| AU2014336638C1 (en) * | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN111285918B (zh) * | 2014-05-06 | 2024-05-31 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
| WO2016030329A1 (en) * | 2014-08-24 | 2016-03-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| EP3212610B1 (en) * | 2014-10-30 | 2020-10-28 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2021115958A (ru) | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы | |
| JP2019519467A5 (enExample) | ||
| JP2015531371A5 (enExample) | ||
| RU2018131636A (ru) | Новые конъюгаты аманитина | |
| RU2010108448A (ru) | Способы индукции конечной дифференцировки | |
| MX2021005808A (es) | Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer. | |
| RU2012141590A (ru) | Соединения для лечения рака | |
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2017538677A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2013521281A5 (enExample) | ||
| Vitale et al. | Stress responses in stromal cells and tumor homeostasis | |
| JP2015517482A5 (enExample) | ||
| JP2014524441A5 (enExample) | ||
| EA201000558A1 (ru) | Производные имидазола | |
| Tan et al. | Intraductal papillary neoplasm of the bile ducts: a case report and literature review | |
| JP2015528814A5 (enExample) | ||
| RU2016147654A (ru) | Соединения для лечения рака | |
| RU2013112871A (ru) | Соединения для лечения рака | |
| RU2016128396A (ru) | Новые способы лечения рака | |
| Guo et al. | Synthesis and preliminary evaluation of novel 99mTc-labeled folate derivative via click reaction for SPECT imaging | |
| RU2018107143A (ru) | Ингибиторы фукозидазы | |
| CA2407592A1 (en) | Small technetium-99m and rhenium labeled agents and methods for imaging tumors | |
| DK1503756T3 (da) | Epothilonderivat til behandling af hepatom og andre cancersygdomme | |
| EA200901180A1 (ru) | Производные тетрагидрохинолина и их применение для лечения злокачественного новообразования |